Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Morel

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|January 25, 2002
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaBertrand Coiffier, Eric Lepage, Josette Briere, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programsCaroline Besson, Danielle Canioni, Eric Lepage, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapyXavier Leleu, Jérome Tamburini, Aldo Roccaro, et al.
Blood|October 25, 2003
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patientsMarc André, Nicolas Mounier, Xavier Leleu, et al.
Blood|February 11, 2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Nicolas Mounier, Josette Briere, Christian Gisselbrecht, et al.
Nature Communications|July 11, 2020
Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolutionRoxane M Pommier, Amélien Sanlaville, Laurie Tonon, et al.
Leukemia Research|February 5, 2010
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)Christian Rose, Sabine Brechignac, Dominique Vassilief, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trialsDavid Sibon, Marion Fournier, Josette Brière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring systemLuca Baldini, Maria Goldaniga, Andrea Guffanti, et al.
Oncoimmunology|May 4, 2016
A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavageColette Dezutter-Dambuyant, Isabelle Durand, Laurent Alberti, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|January 25, 2002
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaBertrand Coiffier, Eric Lepage, Josette Briere, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programsCaroline Besson, Danielle Canioni, Eric Lepage, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapyXavier Leleu, Jérome Tamburini, Aldo Roccaro, et al.
Blood|October 25, 2003
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patientsMarc André, Nicolas Mounier, Xavier Leleu, et al.
Blood|February 11, 2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Nicolas Mounier, Josette Briere, Christian Gisselbrecht, et al.
Nature Communications|July 11, 2020
Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolutionRoxane M Pommier, Amélien Sanlaville, Laurie Tonon, et al.
Leukemia Research|February 5, 2010
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)Christian Rose, Sabine Brechignac, Dominique Vassilief, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trialsDavid Sibon, Marion Fournier, Josette Brière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring systemLuca Baldini, Maria Goldaniga, Andrea Guffanti, et al.
Oncoimmunology|May 4, 2016
A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavageColette Dezutter-Dambuyant, Isabelle Durand, Laurent Alberti, et al.
Pageof 16